Acetylcholinesterase Inhibitors Activate Septohippocampal GABAergic Neurons via Muscarinic but Not Nicotinic Receptors

Min Wu, Samuel S. Newton, Joshua B. Atkins, Changqing Xu, Ronald S. Duman, Meenakshi Alreja

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Acetylcholinesterase (AChE) inhibitors, which increase synaptic levels of available acetylcholine (ACh) by preventing its degradation, are the most extensively prescribed drugs for the treatment of Alzheimer's disease. In animals, AChE inhibitors improve learning and memory, reverse scopolamine-induced amnesia, and produce hippocampal theta rhythm. The medial septum/diagonal band of Broca (MSDB), which maintains hippocampal theta rhythm and associated mnemonic functions via the septohippocampal pathway, is considered a critical locus for mediating the effects of AChE inhibitors. Using electrophysiological recordings and fluorescent labeling techniques to identify living septohippocampal neurons in rat brain slices, we report that AChE inhibitors, in the absence of exogenous ACh, produce a profound excitation in 94% of septohippocampal GABAergic neurons and an inhibition in 24% of septohippocampal cholinergic neurons. The inhibitory and excitatory effects of AChE inhibitors, presumably, occur due to accumulation of ACh that is released locally within the MSDB via axon collaterals of septohippocampal cholinergic neurons. The excitatory effects of AChE inhibitors on septohippocampal GABAergic neurons were blocked by muscarinic but not nicotinic receptor antagonists, especially by the M3 receptor antagonist, 4-diphenylacetoxy-N-methylpiperidine mustard, and not by M1 or M 2/M4 muscarinic receptor antagonists. M3 muscarinic receptor mRNA colocalized with the calcium-binding protein, parvalbumin, a marker of septohippocampal GABAergic neurons. These findings may be useful in designing therapeutic strategies that do not depend on endogenous ACh and may therefore be effective in situations where AChE inhibitors cease to be effective, such as in progressive neurodegeneration.

Original languageEnglish (US)
Pages (from-to)535-543
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume307
Issue number2
DOIs
StatePublished - Nov 1 2003

Fingerprint

GABAergic Neurons
Cholinesterase Inhibitors
Nicotinic Receptors
Cholinergic Agents
Acetylcholine
Diagonal Band of Broca
Theta Rhythm
Cholinergic Neurons
Muscarinic M3 Receptors
Nicotinic Antagonists
Parvalbumins
Mustard Plant
Muscarinic Antagonists
Calcium-Binding Proteins
Scopolamine Hydrobromide
Amnesia
Axons
Alzheimer Disease
Learning
Neurons

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Acetylcholinesterase Inhibitors Activate Septohippocampal GABAergic Neurons via Muscarinic but Not Nicotinic Receptors. / Wu, Min; Newton, Samuel S.; Atkins, Joshua B.; Xu, Changqing; Duman, Ronald S.; Alreja, Meenakshi.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 307, No. 2, 01.11.2003, p. 535-543.

Research output: Contribution to journalArticle

Wu, Min ; Newton, Samuel S. ; Atkins, Joshua B. ; Xu, Changqing ; Duman, Ronald S. ; Alreja, Meenakshi. / Acetylcholinesterase Inhibitors Activate Septohippocampal GABAergic Neurons via Muscarinic but Not Nicotinic Receptors. In: Journal of Pharmacology and Experimental Therapeutics. 2003 ; Vol. 307, No. 2. pp. 535-543.
@article{b758ab8c7c824cebbf4a1f565cf88112,
title = "Acetylcholinesterase Inhibitors Activate Septohippocampal GABAergic Neurons via Muscarinic but Not Nicotinic Receptors",
abstract = "Acetylcholinesterase (AChE) inhibitors, which increase synaptic levels of available acetylcholine (ACh) by preventing its degradation, are the most extensively prescribed drugs for the treatment of Alzheimer's disease. In animals, AChE inhibitors improve learning and memory, reverse scopolamine-induced amnesia, and produce hippocampal theta rhythm. The medial septum/diagonal band of Broca (MSDB), which maintains hippocampal theta rhythm and associated mnemonic functions via the septohippocampal pathway, is considered a critical locus for mediating the effects of AChE inhibitors. Using electrophysiological recordings and fluorescent labeling techniques to identify living septohippocampal neurons in rat brain slices, we report that AChE inhibitors, in the absence of exogenous ACh, produce a profound excitation in 94{\%} of septohippocampal GABAergic neurons and an inhibition in 24{\%} of septohippocampal cholinergic neurons. The inhibitory and excitatory effects of AChE inhibitors, presumably, occur due to accumulation of ACh that is released locally within the MSDB via axon collaterals of septohippocampal cholinergic neurons. The excitatory effects of AChE inhibitors on septohippocampal GABAergic neurons were blocked by muscarinic but not nicotinic receptor antagonists, especially by the M3 receptor antagonist, 4-diphenylacetoxy-N-methylpiperidine mustard, and not by M1 or M 2/M4 muscarinic receptor antagonists. M3 muscarinic receptor mRNA colocalized with the calcium-binding protein, parvalbumin, a marker of septohippocampal GABAergic neurons. These findings may be useful in designing therapeutic strategies that do not depend on endogenous ACh and may therefore be effective in situations where AChE inhibitors cease to be effective, such as in progressive neurodegeneration.",
author = "Min Wu and Newton, {Samuel S.} and Atkins, {Joshua B.} and Changqing Xu and Duman, {Ronald S.} and Meenakshi Alreja",
year = "2003",
month = "11",
day = "1",
doi = "10.1124/jpet.103.052514",
language = "English (US)",
volume = "307",
pages = "535--543",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Acetylcholinesterase Inhibitors Activate Septohippocampal GABAergic Neurons via Muscarinic but Not Nicotinic Receptors

AU - Wu, Min

AU - Newton, Samuel S.

AU - Atkins, Joshua B.

AU - Xu, Changqing

AU - Duman, Ronald S.

AU - Alreja, Meenakshi

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Acetylcholinesterase (AChE) inhibitors, which increase synaptic levels of available acetylcholine (ACh) by preventing its degradation, are the most extensively prescribed drugs for the treatment of Alzheimer's disease. In animals, AChE inhibitors improve learning and memory, reverse scopolamine-induced amnesia, and produce hippocampal theta rhythm. The medial septum/diagonal band of Broca (MSDB), which maintains hippocampal theta rhythm and associated mnemonic functions via the septohippocampal pathway, is considered a critical locus for mediating the effects of AChE inhibitors. Using electrophysiological recordings and fluorescent labeling techniques to identify living septohippocampal neurons in rat brain slices, we report that AChE inhibitors, in the absence of exogenous ACh, produce a profound excitation in 94% of septohippocampal GABAergic neurons and an inhibition in 24% of septohippocampal cholinergic neurons. The inhibitory and excitatory effects of AChE inhibitors, presumably, occur due to accumulation of ACh that is released locally within the MSDB via axon collaterals of septohippocampal cholinergic neurons. The excitatory effects of AChE inhibitors on septohippocampal GABAergic neurons were blocked by muscarinic but not nicotinic receptor antagonists, especially by the M3 receptor antagonist, 4-diphenylacetoxy-N-methylpiperidine mustard, and not by M1 or M 2/M4 muscarinic receptor antagonists. M3 muscarinic receptor mRNA colocalized with the calcium-binding protein, parvalbumin, a marker of septohippocampal GABAergic neurons. These findings may be useful in designing therapeutic strategies that do not depend on endogenous ACh and may therefore be effective in situations where AChE inhibitors cease to be effective, such as in progressive neurodegeneration.

AB - Acetylcholinesterase (AChE) inhibitors, which increase synaptic levels of available acetylcholine (ACh) by preventing its degradation, are the most extensively prescribed drugs for the treatment of Alzheimer's disease. In animals, AChE inhibitors improve learning and memory, reverse scopolamine-induced amnesia, and produce hippocampal theta rhythm. The medial septum/diagonal band of Broca (MSDB), which maintains hippocampal theta rhythm and associated mnemonic functions via the septohippocampal pathway, is considered a critical locus for mediating the effects of AChE inhibitors. Using electrophysiological recordings and fluorescent labeling techniques to identify living septohippocampal neurons in rat brain slices, we report that AChE inhibitors, in the absence of exogenous ACh, produce a profound excitation in 94% of septohippocampal GABAergic neurons and an inhibition in 24% of septohippocampal cholinergic neurons. The inhibitory and excitatory effects of AChE inhibitors, presumably, occur due to accumulation of ACh that is released locally within the MSDB via axon collaterals of septohippocampal cholinergic neurons. The excitatory effects of AChE inhibitors on septohippocampal GABAergic neurons were blocked by muscarinic but not nicotinic receptor antagonists, especially by the M3 receptor antagonist, 4-diphenylacetoxy-N-methylpiperidine mustard, and not by M1 or M 2/M4 muscarinic receptor antagonists. M3 muscarinic receptor mRNA colocalized with the calcium-binding protein, parvalbumin, a marker of septohippocampal GABAergic neurons. These findings may be useful in designing therapeutic strategies that do not depend on endogenous ACh and may therefore be effective in situations where AChE inhibitors cease to be effective, such as in progressive neurodegeneration.

UR - http://www.scopus.com/inward/record.url?scp=0142210243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142210243&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.052514

DO - 10.1124/jpet.103.052514

M3 - Article

C2 - 12966162

AN - SCOPUS:0142210243

VL - 307

SP - 535

EP - 543

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -